drugset

drugset / Trial / NCT05650749

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

NCT05650749 ↗

Phase 1 Recruiting 45 enrolled Stephan Grupp MD PhD Children's Hospital of Philadelphia · collab Gilead Sciences · collab Kite, A Gilead Company · collab National Cancer Institute (NCI) · collab University of Pennsylvania · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.

Timeline

Start: 2023-05-23
Primary completion: 2028-01-30
Completion: 2030-01-30

Publications

Giudice AM, Matlaga S, Roth SL, Gladney W, Groff D, Hofmann TJ, McDaid KS, Pascual-Pasto G, McIntyre B, Zecchino V, Martinez D, Spear TT, Wolpaw AJ, Assenmacher CA, Radaelli E, Pogoriler J, Pawel B, Barrett D, Grupp SA, Maris JM, Bosse KR. D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. Clin Cancer Res. 2025 Dec 15;31(24):5276-5293. doi: 10.1158/1078-0432.CCR-25-0089.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GPC2 CAR T cells	Cell therapy	—	—

Indications